Shuhao Wen
温书豪
Shuhao Wen is a co-founder of XtalPi, an AI-driven drug-discovery company. elsewhere's corpus does not otherwise cover him directly.
AI-generated — may contain errors, please verify.
Coverage
On the Eve of IPO, a Conversation with METiS Pharmaceuticals' Caida Lai: From Formulas on a Whiteboard to "The SpaceX of Pharma"
The story behind the investment.
峰瑞资本·Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
峰瑞资本·Congratulations to FengRui's early-stage portfolio company Lightelligence on its successful IPO: From a Boston Dining Table to Photonic Infrastructure for the AI Era
The World's First Publicly Traded AI Silicon Photonics Chip Company
峰瑞资本·Five Sources Capital Promotes Its First Post-90s Partner
How Do VCs Grow New Capabilities?
暗涌Waves·2025: Three Directions Where AI Is Reshaping Drug Discovery
How Can AI Help Drug Development Cross the "Valley of Death"?
峰瑞资本·January: Arriving at the Realm of Infinity | 5Y News Monthly
The big news from last month.
五源资本·Seeking Entrepreneurs for the Era of Tech Innovation 2.0 | 2024 5Y Capital USD Fund Partner Meeting Recap
They don't just have cross-disciplinary technical integration capabilities — they also bring a global perspective.
五源资本·5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
五源资本·5Y News | 5Y Capital Portfolio Company "Laimang Biotech" Raises 50 Million Yuan in New Funding
Accelerating the clinical translation of ultra-low-dose CAR-T.
五源资本·Congratulations to XtalPi on its successful listing on the Hong Kong Stock Exchange! | 5Y News
"AI + Robotics" builds the first 18C-listed stock, constructing new R&D infrastructure for future industries.
五源资本·Congratulations to XtalPi on its Successful IPO: How FreeS Fund's Research-Driven Approach Learns from Investing
AI + Robotics Creates First 18C Listing — Congratulations to XtalPi
峰瑞资本·Action Is the Simplest Method | 5Y News Monthly
The big news from last month.
五源资本·What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
峰瑞资本·July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
五源资本·From Tech to Business: New Possibilities Brought by ITBT | 5Y Talk
We spoke with five entrepreneurs about their progress and breakthroughs.
五源资本·5Y News | Limmuno Biotech Closes Nearly RMB 100 Million Angel Round
Immunometabolic Reprogramming + AI-Powered Computation for Innovative Cancer Immunotherapy
五源资本·Morningside-backed XtalPi raises over $300 million in new funding | Light Moments
5Y Capital has long been bullish on the application of computational science in the life sciences, hoping that the convergence of IT and biotechnology will soon usher human health into a new era.
五源资本·FreeS Fund received eight recognitions from institutions including *Fortune* (Chinese edition), 36Kr, and the Fund of Funds Alliance.
Do what's right, not what's easy.
峰瑞资本·Harvard x MIT x Stanford x CMU x Berkeley, Meeting Gen Z | FreeS Fund North America Campus Recruitment
Welcome aboard. Join the innovators and build something new.
峰瑞资本·XtalPi Closes $46 Million Series B+ Round | FreeS Fund Deal Brief
Empowering drug R&D organizations worldwide.
峰瑞资本·A Founder's 365 Days: The Days That Got Us Through, and 22 Amazing Moments | FreeS Fund Year-End Special
Here's to exploration, struggle, and perseverance. Happy New Year!
峰瑞资本·
